バーモントにおける急性骨髄性白血病の臨床試験
バーモント内の拠点で、急性骨髄性白血病に関する7件の研究が参加者を募集しています。
バーモント内の都市
公式研究テキスト（英語）
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- University of Vermont Medical Center, Burlington
- University of Vermont and State Agricultural College, Burlington
被験者募集中第2相
18歳〜59歳 · 全性別 · 2026/09/28更新 · NCT05554393MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- University of Vermont Medical Center, Burlington
- University of Vermont and State Agricultural College, Burlington
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT05564390Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- University of Vermont Medical Center, Burlington
- University of Vermont and State Agricultural College, Burlington
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06317649Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- University of Vermont Medical Center, Burlington
- University of Vermont and State Agricultural College, Burlington
被験者募集中第2相
18歳〜59歳 · 全性別 · 2026/09/22更新 · NCT05554406A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- University of Vermont and State Agricultural College, Burlington
被験者募集中第3相
6 Months – 21 Years · 全性別 · 2026/09/17更新 · NCT04293562Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- University of Vermont Medical Center, Burlington
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/20更新 · NCT07007312Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- University of Vermont, Burlington
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/20更新 · NCT06001788ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。